And already, in Indian media, there are starting to be attacks on aryuvedic medicine and the natural (and harmless and cheap) treatments that India has given to the world, all the drugs companies are trying to patent (own) the very substances they promote as worthless natural treatments.
Indian oncology market to grow at 21% CAGR: F&S
Bangalore, July 27, 2010: The Indian oncology market is witnessing strong growth alongside fast-paced development in the pharmaceutical sector. The market is expected to grow at a CAGR of 21 percent from 2008 to 2014, driven by the introduction of new treatments, increasing number of patients on chemotherapy, and improved access to modern cancer therapies, according to a new report from Frost & Sullivan (F&S).
Cancer is one of the 10 leading causes of death in India. Nearly half the cases are curable if detected early. Due to the high prevalence of cancer, the oncology market is witnessing fast-paced growth. High spending on therapeutic drugs for cancer in the emerging economies including India is fuelling market growth.
"With the expanding base of patients undergoing chemotherapy in the major markets and greater access to modern therapies, cancer drugs are poised for widespread uptake," noted an F&S analyst, adding: "Moreover, the increase in the aging population is another factor contributing positive momentum for the market." A 40 to 50 percent increase in incidences can be seen for some of the major cancer indications such a prostate, breast, ovarian, and head and neck cancers. Also the high prevalence of smoking is loading to the proliferation in the number of patients afflicted with lung cancer.
Trends indicate that the incidence of cancer is set to assume dangerous proportions in the future, making the disease one of the major chronic diseases that will continue to impact people's lives. Going forward, greater progress in cancer therapy is envisioned along with more light being thrown on the cause of the disease. Yet, it remains to be seen how much the refinement in the present detection diagnostic, and therapeutic technologies will help in containing the spread of the disease. Large quantities of generic drugs are available in the market for cancer treatment. Chemotherapy is highly genericized, said the F&S report, pointing out that these products are low-priced and hence place restrictions on potential revenues.
In this market with increasing competition and generic players, it is important to strategically position products as early in their life cycle as possible to generate the most revenue prior to patent expiration. For the competitive chemotherapy market, showing superior efficacy and less toxicity in combination with targeted therapy drugs is one of the best ways to distinguish the product over others.
"To be successful in the cancer market of the future, it is imperative for product to be established as an integral part of the standard combination therapy regimen. This will guarantee strong revenue and the most value to patients," said the analyst.
Identifying optimal drug combinations, which significantly increase median survival, tumor resolution and reduce toxicity and adverse effects should be the prime task for companies in the cancer therapeutic market, the report mentioned